BACKGROUND: Interleukins IL-4, Il-5, IL-10, IL-13 and IL-33 play an important role in atopic dermatitis patients. The aim of our study is to address several knowledge gaps in the understanding of interleukin dynamics in atopic dermatitis patients and the effects of dupilumab treatment. METHOD: We conducted an assessment of plasma levels of interleukins IL-4, IL-5, IL-10, IL-13 and IL-33 in 89 AD patients and in 44 healthy individuals as a control group. The group of AD patients consisted of 27 patients treated with dupilumab (15 men, 12 women) at a mean age of 44.8 years and 62 patients without dupilumab treatment (35 women and 27 men) at a mean age of 46.3 years. The control group consisted of 44 healthy subjects (22 men, 22 women), at a mean age of 43.3 years. Patients were treated with a standard dose of dupilumab, 300 mg s.c. every two weeks. For screening analysis of plasma levels of selected cytokines, the performance assay Human cytokine Luminex was used. Blood samples were unstimulated and stimulated with phorbol myristate acetate and ionomycin. This stimulation provides non-specific stimulation of innate and adaptive immunity cells and increases their cytokine production. The level of interleukins IL-4, IL-5, IL-10, IL-13 and IL-33 were compared in AD patients with the results in control group. Nonparametric Kruskal-Wallis analysis of variance with post-hoc Dunn's test with Bonferroni modification of significance level was used. RESULTS: The significantly higher plasma level of stimulated IL-5 was confirmed in AD patients treated with dupilumab and significantly higher plasma IL-10 levels were confirmed in both dupilumab and non-dupilumab treated patients compared to control group. Stimulated IL-4 levels are significantly higher in patients treated with dupilumab compared to patients without dupilumab. The significant difference in IL-13 and IL-33 in AD patients compared to control group was not confirmed. CONCLUSION: By identifying significant differences in IL-5 and IL-10 plasma levels, our study highlights potential markers that could improve AD diagnosis and treatment monitoring. Our results contribute to a deeper understanding of how dupilumab alters immune signaling and may inform the development of additional biomarkers and targeted therapies for AD.

Department of Clinical Immunology and Allergy Faculty Hospital and Medical Faculty of Charles University Hradec Králové Czechia

Department of Dermatology and Venereology Faculty Hospital and Medical Faculty of Charles University Hradec Králové Czechia

Department of Medical Biophysics Medical Faculty of Charles University Hradec Králové Czechia

Zobrazit více v PubMed

Krupka-Olek M, Bożek A, Aebisher D, Bartusik-Aebisher D, Cieślar G, Kawczyk-Krupka A. Potential aspects of the use of cytokines in atopic dermatitis. Biomedicines. (2024) 12:867. doi:  10.3390/biomedicines12040867, PMID: PubMed DOI PMC

Abuabara K, Hoffstad O, Troxel AB, Gelfand JM, McCulloch CE, Margolis DJ. Patterns and predictors of atopic dermatitis disease control past childhood: An observational cohort study. J Allergy Clin Immunol. (2018) 141:778–80. doi:  10.1016/j.jaci.2017.05.031, PMID: PubMed DOI PMC

Abuabara K, Yu AM, Okhovat JP, Allen IE, Langan SM. The prevalence of atopic dermatitis beyond childhood: A systematic review and meta analysis of longitudinal studies. Allergy. (2018) 73:696–704. doi:  10.1111/all.13320, PMID: PubMed DOI PMC

Le Floc’h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. (2020) 75:1188–204. doi:  10.1111/all.14151, PMID: PubMed DOI PMC

Hou T, Sun X, Zhu J, Hon KL, Jiang P, Chu IM, et al. IL-37 ameliorating allergic inflammation in atopic dermatitis through regulating microbiota and AMPK-mTOR signaling pathway-modulated autophagy mechanism. Front Immunol. (2020) 11:752. doi:  10.3389/fimmu.2020.00752, PMID: PubMed DOI PMC

Dougan M, Dranoff G, Dougan SK. GM-CSF, IL-3, and IL-5 family of cytokines: Regulators of inflammation. Immunity. (2019) 50:796–811. doi:  10.1016/j.immuni.2019.03.022, PMID: PubMed DOI

Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. (2002) 347:1151–60. doi:  10.1056/NEJMoa021481, PMID: PubMed DOI

Howell MD, Jones JF, Kisich KO, Streib JE, Gallo RL, Leung DY. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol. (2004) 172:1763–7. doi:  10.4049/jimmunol.172.3.1763, PMID: PubMed DOI

Ohmen JD, Hanifin JM, Nickoloff BJ, Rea TH, Wyzykowski R, Kim J, et al. Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J Immunol. (1995) 154:1956–63. doi:  10.4049/jimmunol.154.4.1956, PMID: PubMed DOI

Howell MD, Novak N, Bieber T, Pastore S, Girolomoni G, Boguniewicz M, et al. Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol. (2005) 125:738–45. doi:  10.1111/j.0022-202X.2005.23776.x, PMID: PubMed DOI

Mitroi GG, Pleşea EL, Mitroi GF, Mitroi MR, Neagoe CD, Ianoşi SL. Exploring the potential of IL-4 and IL-13 plasma levels as biomarkers in atopic dermatitis. Life. (2024) 14:352. doi:  10.3390/life14030352, PMID: PubMed DOI PMC

Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry. Allergy. (2020) 75:116–26. doi:  10.1111/all.14080, PMID: PubMed DOI

Nettis E, Ferrucci SM, Ortoncelli M, Pellacani G, Foti C, Di Leo E, et al. Use of dupilumab in 543 adult patients with moderate-to-severe atopic dermatitis: A multicenter, retrospective study. J Investig Allergol Clin Immunol. (2022) 32:124–32. doi:  10.18176/jiaci.0641, PMID: PubMed DOI

Scibiorek M, Mthembu N, Mangali S, Ngomti A, Ikwegbue P, Brombacher F, et al. IL-4Rα signalling in B cells and T cells play differential roles in acute and chronic atopic dermatitis. Sci Rep. (2023) 13:144. doi:  10.1038/s41598-022-26637-6, PMID: PubMed DOI PMC

Bakker DS, Ariens LFM, Giovannone B, Hijnen D, Delemarre EM, Knol E, et al. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with Dupilumab using a combination of serum biomarkers. Allergy. (2020) 75:3287–9. doi:  10.1111/all.14492, PMID: PubMed DOI PMC

Brombacher F. The role of interleukin-13 in infectious diseases and allergy. Bioessays. (2000) 22:646–56. doi:  10.1002/1521-1878(200007)22:7<646::AID-BIES7>3.0.CO;2-9 PubMed DOI

Iwaszko M, Biały S, Bogunia-Kubik K. Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis. Cells. (2021) 10:3000. doi:  10.3390/cells10113000, PMID: PubMed DOI PMC

Mitroi GG, Stoica LE, Mitroi GF, Mitroi MR, Tutunaru CV, Ică OM, et al. Atopic dermatitis with multiple comorbidities treated with dupilumab. A case report and review of the literature regarding the safety of dupilumab. Life. (2022) 12:1670. doi:  10.3390/life12101670, PMID: PubMed DOI PMC

Melo-Cardenas J, Bezavada L, Crawford JC, Gurbuxani S, Cotton A, Kang G, et al. IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood. (2022) 140:2805–17. doi:  10.1182/blood.2022017326, PMID: PubMed DOI PMC

Wu Y, Gu C, Wang S, Yin H, Qiu Z, Luo Y, et al. Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of Dupilumab. Br J Dermatol. (2023) 188:649–60. doi:  10.1093/bjd/ljad032, PMID: PubMed DOI

May RD, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. Cytokine. (2015) 75:89–116. doi:  10.1016/j.cyto.2015.05.018, PMID: PubMed DOI

Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol. (2014) 133:1626–34. doi:  10.1016/j.jaci.2014.03.003, PMID: PubMed DOI PMC

Gambichler T, Kreuter A, Tomi NS, Othlinghaus N, Altmeyer P, Skrygan M. Gene expression of cytokines in atopic eczema before and after ultraviolet A1 phototherapy. Br J Dermatol. (2008) 158:1117–20. doi:  10.1111/j.1365-2133.2008.08498.x, PMID: PubMed DOI

Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol. (2004) 114:887–95. doi:  10.1016/j.jaci.2004.05.066, PMID: PubMed DOI

Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. (2020) 75:54–62. doi:  10.1111/all.13954, PMID: PubMed DOI

Kamphuis E, Boesjes CM, Loman L, Bakker DS, Poelhekken M, Zuithoff NPA, et al. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry. Pediatr Allergy Immunol. (2022) 33:e13887. doi:  10.1111/pai.13887, PMID: PubMed DOI PMC

Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. (2001) 10:11–8. doi:  10.1034/j.1600-0625.2001.100102.x, PMID: PubMed DOI

Staples E, Ingram RJ, Atherton JC, Robinson K. Optimising the quantification of cytokines present at low concentrations in small human mucosal tissue samples using Luminex assays. J Immunol Methods. (2013) 394:1–9. doi:  10.1016/j.jim.2013.04.009, PMID: PubMed DOI PMC

Godoy-Ramirez K, Franck K, Mahdavifar S, Andersson L, Gaines H. Optimum culture conditions for specific and nonspecific activation of whole blood and PBMC for intracellular cytokine assessment by flow cytometry. J Immunol Methods. (2004) 292:1–15. doi:  10.1016/j.jim.2004.04.028, PMID: PubMed DOI

Junttila IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. (2018) 9:888. doi:  10.3389/fimmu.2018.00888, PMID: PubMed DOI PMC

Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. (2021) 51:915–31. doi:  10.1111/cea.13954, PMID: PubMed DOI PMC

Deeks ED. Dupilumab: A review in moderate to severe asthma. Drugs. (2019) 79:1885–95. doi:  10.1007/s40265-019-01221-x, PMID: PubMed DOI

Roesner LM, Bridgewood C, McGonagle D, Wittmann M. Dupilumab: an opportunity to unravel PubMed DOI

Suwanchote S, Waitayangkoon P, Chancheewa B, Inthanachai T, Niwetbowornchai N, Edwards SW, et al. Role of antimicrobial peptides in atopic dermatitis. Int J Dermatol. (2022) 61:532–40. doi:  10.1111/ijd.15814, PMID: PubMed DOI

Carlini V, Noonan DM, Abdalalem E, Goletti D, Sansone C, Calabrone L, et al. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front Immunol. (2023) 14:1161067. doi:  10.3389/fimmu.2023.1161067, PMID: PubMed DOI PMC

Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. iv. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. (1989) 170:2081–95. doi:  10.1084/jem.170.6.2081, PMID: PubMed DOI PMC

Wilke CM, Wei S, Wang L, Kryczek I, Kao J, Zou W. Dual biological effects of the cytokines interleukin-10 and interferon-gamma. Cancer Immunol Immunother. (2011) 60:1529–41. doi:  10.1007/s00262-011-1104-5, PMID: PubMed DOI PMC

Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. (2012) 32:23–63. doi:  10.1615/critrevimmunol.v32.i1.30, PMID: PubMed DOI PMC

Frampton JE, Blair HA. Dupilumab: A review in moderate-to-severe atopic dermatitis. Am J Clin Dermatol. (2018) 19:617–24. doi:  10.1007/s40257-018-0370-9, PMID: PubMed DOI

Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. (2014) 371:130–9. doi:  10.1056/NEJMoa1314768, PMID: PubMed DOI

Pelaia C, Heffler E, Crimi C, Maglio A, Vatrella A, Pelaia G, et al. Interleukins 4 and 13 in asthma: key pathophysiologic cytokines and druggable molecular targets. Front Pharmacol. (2022) 13:851940. doi:  10.3389/fphar.2022.851940, PMID: PubMed DOI PMC

Berdyshev E, Goleva E, Bissonnette R, Bronova I, Bronoff AS, Richers BN, et al. Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. Allergy. (2022) 77:3388–97. doi:  10.1111/all.15432, PMID: PubMed DOI

Čelakovská J, Čermáková E, Boudková P, Andrýs C, Krejsek J. The association between eosinophils (CD16 PubMed DOI PMC

Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract. (2022) 10:2695–709. doi:  10.1016/j.jaip.2022.05.019, PMID: PubMed DOI

Piehler D, Stenzel W, Grahnert A, Held J, Richter L, Köhler G, et al. Eosinophils contribute to IL-4 production and shape T-helper cytokine profile and inflammatory response in pulmonary cryptococcosis. Am J Pathol. (2011) 179:733–44. doi:  10.1016/j.ajpath.2011.04.025, PMID: PubMed DOI PMC

Pelaia C, Pelaia G, Crimi C, Maglio A, Armentaro G, Calabrese C, et al. Biological therapy of severe asthma with dupilumab, a dual receptor antagonist of interleukins 4 and 13. Vaccines (Basel). (2022) 10:974. doi:  10.3390/vaccines10060974, PMID: PubMed DOI PMC

Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. (2015) 7:1043–58. doi:  10.2217/imt.15.69, PMID: PubMed DOI

Hoving JC. Targeting IL-13 as a host-directed therapy against ulcerative colitis. Front Cell Infect Microbiol. (2018) 8:395. doi:  10.3389/fcimb.2018.00395, PMID: PubMed DOI PMC

Mannon P, Reinisch W. Interleukin 13 and its role in gut defence and inflammation. Gut. (2012) 61:1765–73. doi:  10.1136/gutjnl-2012-303461, PMID: PubMed DOI

Miller AM. Role of IL-33 in inflammation and disease. J Inflammation (Lond). (2011) 8:22. doi:  10.1186/1476-9255-8-22, PMID: PubMed DOI PMC

Cayrol C, Girard JP. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol Rev. (2018) 281:154–68. doi:  10.1111/imr.12619, PMID: PubMed DOI

Wang X, Cheng Z. Cross-sectional studies: strengths, weaknesses, and recommendations. Chest. (2020) 158:S65–71. doi:  10.1016/j.chest.2020.03.012, PMID: PubMed DOI